Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Salpep Biotechnology

1996 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
3 FINANCING ROUNDS
Description

Developer of novel anti-inflammatory molecules as therapeutic agents. The company discovers and develops anti-inflammatory therapeutic agents for treating asthma and intestinal motility disturbances caused by allergic and endotoxemic reactions.

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
AtheroMedix
Primary Office
  • 3330 Hospital Drive Northwest
  • Calgary, Alberta
  • Canada

+1 (403) 000-0000

Salpep Biotechnology Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Salpep Biotechnology‘s full profile, request access.

Request full access to PitchBook

Salpep Biotechnology Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Salpep Biotechnology‘s full profile, request access.

Request full access to PitchBook

Salpep Biotechnology Executive Team (4)

Name Title Board
Seat
Contact
Info
Dean Befus Ph.D Co-Founder
Joseph Davison Ph.D Co-Founder
Ronald Mathison Ph.D Co-Founder
Marc Engelsgjerd MD Vice President